Monocyte human leukocyte antigen-DR transcriptional downregulation by cortisol during septic shock

American Journal of Respiratory and Critical Care Medicine

Volumn 169, Issue 10, 2004, Pages 1144-1151

  Tulzo, Yves Le ^a,b   Pangault, Celine ^a   Amiot, Laurence ^a   Guilloux, Valérie ^a   Tribut, Olivier ^a   Arvieux, Cédric ^a   Camus, Christophe ^a   Fauchet, Renée ^a   Thomas, Rémi ^a   Drénou, Bernard ^a  

^a RENNES UNIVERSITY HOSPITAL   (France)

^b PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

Author keywords

Class II transactivator A; Immune paralysis; Infection; Major histocompatibility complex type II

Indexed keywords

CATECHOLAMINE; DEXAMETHASONE; GLUCOCORTICOID; HLA DR ANTIGEN; HYDROCORTISONE; INTERLEUKIN 10; TRANSACTIVATOR PROTEIN;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CELL LOSS; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DEATH; DISEASE SEVERITY; DOWN REGULATION; DRUG EFFECT; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HYDROCORTISONE BLOOD LEVEL; MALE; MONOCYTE; PRIORITY JOURNAL; PROTEIN CONTENT; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCORING SYSTEM; SEPTIC SHOCK; SUPERINFECTION; TRANSCRIPTION REGULATION;

ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; COHORT STUDIES; DOWN-REGULATION; FEMALE; FLOW CYTOMETRY; HLA-DR ANTIGENS; HUMANS; HYDROCORTISONE; IMMUNOSUPPRESSION; LEUKOCYTES; MALE; MIDDLE AGED; MONOCYTES; MULTIVARIATE ANALYSIS; PROBABILITY; REFERENCE VALUES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SEVERITY OF ILLNESS INDEX; SHOCK, SEPTIC; SURVIVAL RATE;

EID: 2442501750     PISSN: 00030805     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Friedman G, Silva E, Vincent JL. Has the mortality of septic shock changed with time. Crit Care Med 1998;26:2078-2086.
2. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992;20:864-874.
3. +T lymphocytes in humans. J Immunol 2001;166:6952-6963.
4. Le Tulzo Y, Pangault C, Gacouin A, Guilloux V, Tribut O, Amiot L, Tattevin P, Thomas R, Fauchet R, Drenou B. Early circulating lymphocyte apoptosis in human septic shock is associated with poor outcome. Shock 2002;18:487-494.
5. Munoz C, Carlet J, Fitting C, Misset B, Bleriot JP, Cavaillon JM. Dysregulation of in vitro cytokine production by monocytes during sepsis. J Clin Invest 1991;88:1747-1754.
6. Docke WD, Randow F, Syrbe U, Krausch D, Asadullah K, Reinke P, Volk HD, Kox W. Monocyte deactivation in septic patients: restoration by IFN-gamma treatment. Nat Med 1997;3:678-681.
7. DeRijk R, Michelson D, Karp B, Petrides J, Galliven E, Deuster P, Paciotti G, Gold PW, Sternberg EM. Exercise and circadian rhythm-induced variations in plasma cortisol differentially regulate interleukin-1 beta (IL-1 beta), IL-6, and tumor necrosis factor-alpha (TNF alpha) production in humans: high sensitivity of TNF alpha and resistance of IL-6. J Clin Endocrinol Metab 1997;82:2182-2191.
8. Le Tulzo Y, Shenkar R, Kaneko D, Moine P, Fantuzzi G, Dinarello CA, Abraham E. Hemorrhage increases cytokine expression in lung mononuclear cells in mice: involvement of catecholamines in nuclear factor-kappaB regulation and cytokine expression. J Clin Invest 1997; 99:1516-1524.
9. Wang P, Wu P, Siegel MI, Egan RW, Billah MM. Interleukin (IL)-10 inhibits nuclear factor kappa B (NF kappa B) activation in human monocytes: IL-10 and IL-4 suppress cytokine synthesis by different mechanisms. J Biol Chem 1995;270:9558-9563.
10. Reddy RC, Chen GH, Newstead MW, Moore T, Zeng X, Tateda K, Standiford TJ. Alveolar macrophage deactivation in murine septic peritonitis: role of interleukin 10. Infect Immun 2001;69:1394-1401.
11. Fumeaux T, Pugin J. Role of interleukin-10 in the intracellular sequestration of human leukocyte antigen-DR in monocytes during septic shock. Am J Respir Crit Care Med 2002;166:1475-1482.
12. Wolk K, Kunz S, Crompton NE, Volk HD, Sabat R. Multiple mechanisms of reduced major histocompatibility complex class II expression in endotoxin tolerance. J Biol Chem 2003;278:18030-18036.
13. Nagarajan UM, Bushey A, Boss JM. Modulation of gene expression by the MHC class II transactivator. J Immunol 2002;169:5078-5088.
14. Boss JM. Regulation of transcription of MHC class II genes. Curr Opin Immunol 1997;9:107-113.
15. Muhlethaler-Mottet A, Otten LA, Steimle V, Mach B. Expression of MHC class II molecules in different cellular and functional compartments is controlled by differential usage of multiple promoters of the transactivator CIITA. EMBO J 1997;16:2851-2860.
16. Le Tulzo YP, Le Friec C, Lavoué G, Guilloux S, Tribut V, Amiot O, Tattevin L, Fauchet P, Thomas R, Drénou RB. Septic shock monocyte HLA-DR and GM-CSF receptor (CD116) low expression is related to severity [abstract]. Am J Respir Cell Mol Biol 2002;165:B31.
17. Le Gall JR, Lemeshow S, Saulnier F. A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. JAMA 1993;270:2957-2963.
18. Le Gall JR, Klar J, Lemeshow S, Saulnier F, Alberti C, Artigas A, Teres D. The logistic organ dysfunction system: a new way to assess organ dysfunction in the intensive care unit: ICU Scoring Group. JAMA 1996;276:802-810.
19. Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. CDC definitions for nosocomial infections, 1988. Am J Infect Control 1988;16:128-140.
20. Lin RY, Astiz ME, Saxon JC, Rackow EC. Altered leukocyte immunophenotypes in septic shock: studies of HLA-DR, CD11b, CD14, and IL-2R expression. Chest 1993;104:847-853.
21. Oczenski W, Krenn H, Jilch R, Watzka H, Waldenberger F, Koller U, Schwarz S, Fitzgerald RD. HLA-DR as a marker for increased risk for systemic inflammation and septic complications after cardiac surgery. Intensive Care Med 2003;29:1253-1257.
22. Perry SE, Mostafa SM, Wenstone R, Shenkin A, McLaughlin PJ. Is low monocyte HLA-DR expression helpful to predict outcome in severe sepsis? Intensive Care Med 2003;29:1245-1252.
23. Muller Kobold AC, Tulleken JE, Zijlstra JG, Sluiter W, Hermans J, Kallenberg CG, Cohen Tervaert JW. Leukocyte activation in sepsis: correlations with disease state and mortality. Intensive Care Med 2000; 26:883-892.
24. Monneret G, Elmenkouri N, Bohe J, Debard AL, Gutowski MC, Bienvenu J, Lepape A. Analytical requirements for measuring monocytic human lymphocyte antigen DR by flow cytometry: application to the monitoring of patients with septic shock. Clin Chem 2002;48:1589-1592.
25. Drossou-Agakidou V, Kanakoudi-Tsakalidou F, Sarafidis K, Tzimouli V, Taparkou A, Kremenopoulos G, Germenis A. In vivo effect of rhGM-CSF and rhG-CSF on monocyte HLA-DR expression of septic neonates. Cytokine 2002;18:260-265.
26. Flohe S, Lendemans S, Selbach C, Waydhas C, Ackermann M, Schade FU, Kreuzfelder E. Effect of granulocyte-macrophage colony-stimulating factor on the immune response of circulating monocytes after severe trauma. Crit Care Med 2003;31:2462-2469.
27. Presneill JJ, Harris T, Stewart AG, Cade JF, Wilson JW. A randomized phase II trial of granulocyte-macrophage colony-stimulating factor therapy in severe sepsis with respiratory dysfunction. Am J Respir Crit Care Med 2002;166:138-143.
28. Kox WJ, Bone RC, Krausch D, Docke WD, Kox SN, Wauer H, Egerer K, Quemer S, Asadullah K, von Baehr R, et al. Interferon gamma-1b in the treatment of compensatory anti-inflammatory response syndrome: a new approach: proof of principle. Arch Intern Med 1997; 157:389-393.
29. Cheng AC, Stephens DP, Anstey NM, Currie BJ. Adjunctive granulocyte colony-stimulating factor for treatment of septic shock due to melioidosis. Clin Infect Dis 2004;38:32-37.
30. Carr R, Modi N, Dore C. G-CSF and GM-CSF for treating or preventing neonatal infections. Cochrane Database Syst Rev 2003;CD003066.
31. Root RK, Lodato RF, Patrick W, Cade JF, Fotheringham N, Milwee S, Vincent JL, Torres A, Rello J, Nelson S. Multicenter, double-blind, placebo-controlled study of the use of filgrastim in patients hospitalized with pneumonia and severe sepsis. Crit Care Med 2003;31:367-373.
32. Watanabe Y, Lee S, Allison AC. Control of the expression of a class II major histocompatibility gene (HLA-DR) in various human cell types: down-regulation by IL-1 but not by IL-6, prostaglandin E2, or glucocorticoids. Scand J Immunol 1990;32:601-609.
33. Asadullah K, Woiciechowsky C, Docke WD, Egerer K, Kox WJ, Vogel S, Sterry W, Volk HD. Very low monocytic HLA-DR expression indicates high risk of infection: immunomonitoring for patients after neurosurgery and patients during high dose steroid therapy. Eur J Emerg Med 1995;2:184-190.
34. Fontes JD, Kanazawa S, Jean D, Peterlin BM. Interactions between the class II transactivator and CREB binding protein increase transcription of major histocompatibility complex class II genes. Mol Cell Biol 1999;19:941-947.
35. Schwiebert LM, Schleimer RP, Radka SF, Ono SJ. Modulation of MHC class II expression in human cells by dexamethasone. Cell Immunol 1995;165:12-19.
36. Haveman JW, van den Berg AP, van den Berk JM, Mesander G, Slooff MJ, de Leij LH, The TH. Low HLA-DR expression on peripheral blood monocytes predicts bacterial sepsis after liver transplantation: relation with prednisolone intake. Transpl Infect Dis 1999;1:146-152.
37. Annane D, Sebille V, Troche G, Raphael JC, Gajdos P, Bellissant E. A 3-level prognostic classification in septic shock based on cortisol levels and cortisol response to corticotropin. JAMA 2000;283:1038-1045.
38. Annane D, Sebille V, Charpentier C, Bollaert PE, Francois B, Korach JM, Capellier G, Cohen Y, Azoulay E, Troche G, et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 2002;288:862-871.
39. Keh D, Boehnke T, Weber-Cartens S, Schulz C Ahlers O, Bercker S, Volk HD, Doecke WD, Falke KJ, Gerlach H. Immunologic and hemodynamic effects of "low-dose" hydrocortisone in septic shock: a double-blind, randomized, placebo-controlled, crossover study. Am J Respir Crit Care Med 2003;167:512-520.
40. Schreiber S, Rosenstiel P, Hampe J, Nikolaus S, Groessner B, Schottelius A, Kuhbacher T, Hamling J, Folsch UR, Seegert D. Activation of signal transducer and activator of transcription (STAT) 1 in human chronic inflammatory bowel disease. Gut 2002;51:379-385.
41. Nickerson K, Sisk TJ, Inohara N, Yee CS, Kennell J, Cho MC, Yannie PJII, Nunez G, Chang CH. Dendritic cell-specific MHC class II transactivator contains a caspase recruitment domain that confers potent transactivation activity. J Biol Chem 2001;276:19089-19093.